Authors Emelia Priscilla Imbeah Department of Medical Pharmacology, University of Ghana Medical School, Accra, Ghana https://orcid.org/0000-0003-0379-3395 Ofosua Adi-Dako Department of Pharmaceutics and Microbiology, School of Pharmacy, University of Ghana, Accra, Ghana https://orcid.org/0000-0002-5166-2042 Benoit N’guessan Department of Pharmacology and Toxicology, School of Pharmacy, University of Ghana, Accra, Ghana https://orcid.org/0000-0002-0749-2218 Kennedy Kwami Edem Kukuia Department of Medical Pharmacology, University of Ghana Medical School, Accra, Ghana https://orcid.org/0000-0003-2948-9615 Benedicta Obenewaa Dankyi Department of Medical Pharmacology, University of Ghana Medical School, Accra, Ghana https://orcid.org/0000-0001-6322-8609 Ismaila Adams Department of Medical Pharmacology, University of Ghana Medical School, Accra, Ghana https://orcid.org/0000-0001-7113-3888 Ebenezer Ofori-Attah Department of Clinical Pathology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana Regina Appiah-Opong Department of Clinical Pathology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana https://orcid.org/0000-0003-4219-7107 Seth Kwabena Amponsah Department of Medical Pharmacology, University of Ghana Medical School, Accra, Ghana https://orcid.org/0000-0001-7411-0972 DOI: https://doi.org/10.5599/admet.1474 Abstract

Levodopa is routinely co-administered with carbidopa in the management of Parkinson’s disease. Although the aforementioned combination therapy is effective, there may be fluctuating plasma levels of levodopa after oral administration. We formulated and evaluated the kinetic characteristics of the chitosan-pectin-based multiparticulate matrix of levodopa and carbidopa. Pectin was extracted from the cocoa husk, and the chitosan-pectin-based matrix was prepared by wet granulation. Formulations were evaluated for drug-excipient compatibility, drug content, precompression properties and in vitro release. For pharmacokinetic evaluation, rats were put into groups and administered either chitosan-pectin based matrix of levodopa/carbidopa, Sinemet® CR or levodopa/carbidopa immediate release powder. Rats were administered the different formulations of levodopa/carbidopa (20/5 mg/kg) per os every 12 hours. The pharmacokinetic parameters of levodopa were estimated for the various treatment groups. The percentage content of levodopa and carbidopa in the various formulations was within the acceptance criteria. The AUC0-24 for levodopa/carbidopa multiparticulate matrix (Formulation 3: 484.98 ± 18.70 µg.hr/mL); Formulation 4: 535.60 ± 33.04 µg.hr/mL), and Cmax (Formulation 3: 36.28 ± 1.52 μg/mL; Formulation 4: 34.80 ± 2.19 μg/mL) were higher than Sinemet® CR (AUC0-24 262.84 ± 16.73 µg.hr/mL and Cmax 30.62 ± 3.37 μg/mL). The t1/2 of the new formulation was longer compared to Sinemet® CR.

Downloads

Download data is not yet available.